Search

The document discusses genomic mechanisms associated with resistance to PDL1-blockade in a patient with mantle cell lymphoma. It highlights the importance of disrupting the PD1/PDL1 axis in cancer treatment and describes acquired resistance mechanisms, including upregulated PDL1 expression due to a CD274 structural variant. The patient underwent treatment with atezolizumab and experienced disease recurrence, leading to further genomic characterization and subsequent therapy adjustments. The findings suggest potential implications for personalized treatment approaches in various cancers where PDL1 blockade is utilized. [Extracted from the article]

Summary: We reviewed cases with aggressive B‐cell non‐Hodgkin lymphoma who relapsed or progressed following glofitamab. The prognosis was poor, with low rates of response to subsequent salvage therapies, and a median overall survival of 4.1 months from the time of progression. There were high rates of CD20 loss (59%) at the time of relapse. In a field where CD20 × CD3 bispecific antibodies are entering routine clinical use, our experience highlights a potential means of resistance. It illustrates both the need to further characterise mechanisms of CD20 loss, and to pursue clinical trials of novel non‐CD20‐directed treatments in this cohort. [ABSTRACT FROM AUTHOR]

The article discusses the rates of discordant CD20 status in adult B-cell acute lymphoblastic leukemia (B-ALL) as determined by flow cytometry and immunohistochemistry. The study found a 13% discordance rate between the two methods, with flow cytometry showing more sensitivity in detecting CD20 expression. The implications of these findings on therapeutic choices, particularly regarding the addition of rituximab, are highlighted, emphasizing the need for accurate assessment of CD20 expression in B-ALL cases. The study also raises broader issues regarding the definition of antigen positivity and the importance of consensus on these definitions for targeted immunotherapies. [Extracted from the article]